The Australia-based Starpharma on Tuesday announced that its VivaGel-coated condom will be sold by SSL Global, the P of the Durex condom brand, Bloomberg reports. Starpharma expects to earn more than $81 million in royalties and other payments through the deal with SSL. VivaGel is a microbicide designed to prevent the transmission of sexually transmitted infections, including HIV and genital herpes, according to Bloomberg. Starpharma also aims to strengthen the gel for consume on its own as a vaginal microbicide. The agreement provides the rights to dispose of the VivaGel condom in “most of the beget,” including Europe and the U.S., Starpharma said in a release (Bennett, Bloomberg, 9/9).

“We are peculiarly satisfied to be working with a company such as SSL, which has the capabilities and marketing aptitude to rapidly start the ball rolling the goods through registration and into the supermarket,” Starpharma CEO Jackie Fairley said. SSL has an approximate 30% share of the branded condom market worldwide and sells in more than 100 countries. Global condom retail sales deceive been estimated at close to $3.2 billion (Starpharma saving, 9/9).

Reprinted with feather permission from http://www.kaisernetwork.org. You can view the undivided Kaiser Regularly Health Regulation Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Fettle Policy Report is published for kaisernetwork.org, a unshackled service of The Henry J. Kaiser Family Cellar.

© 2008 Prediction Put up Company and Kaiser Stock Underpinning. All rights reserved.

Kaufen viagra